• Users Online: 18
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2019  |  Volume : 6  |  Issue : 4  |  Page : 272-273

Blonanserin overdose: A case report

1 Department of Psychiatry and Behavioural Sciences, SPS Hospitals, Ludhiana, Punjab, India
2 Department of Medicine, SPS Hospitals, Ludhiana, Punjab, India

Date of Submission14-Nov-2018
Date of Decision08-Mar-2019
Date of Acceptance15-Aug-2019
Date of Web Publication21-Nov-2019

Correspondence Address:
Sandeep Kumar Goyal
Department of Psychiatry and Behavioural Sciences, SPS Hospitals, Ludhiana, Punjab
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/cjhr.cjhr_163_18

Rights and Permissions

How to cite this article:
Goyal SK, Singh P. Blonanserin overdose: A case report. CHRISMED J Health Res 2019;6:272-3

How to cite this URL:
Goyal SK, Singh P. Blonanserin overdose: A case report. CHRISMED J Health Res [serial online] 2019 [cited 2021 Mar 6];6:272-3. Available from: https://www.cjhr.org/text.asp?2019/6/4/272/271328


Blonanserin is an “atypical antipsychotic” which is indicated for the treatment of schizophrenia. It is approved for use in Japan and South Korea.[1] In India, it was approved as a second-line drug for the use in adults who have schizophrenia in 2012.[2]

In a meta-analysis, blonanserin was found to have a lower risk (0.31) of hyperprolactinemia than haloperidol and risperidone. Blonanserin had a lower risk of akathisia (Risk ratio (RR) 0.54) as compared to haloperidol, whereas it had a higher risk (RR 1.62) as compared to risperidone.[3]

Blonanserin-induced dyskinesia and akathisia are reported, but on detailed search, we could not find any case report of an overdose of blonanserin.[4],[5]

We describe a case report of blonanserin overdose.

  Case Report Top

A 23-year-old female patient with a diagnosis of schizophrenia since 2014 was on treatment from our department since May 2018. She was started on blonanserin and clonazepam. She showed significant improvement with treatment and was doing well on 8 mg of blonanserin and 0.25 of clonazepam. She had no suspiciousness, auditory hallucinations, self-muttering, or self-smiling. She had no sialorrhea, slurring of speech, tremors of body, or akathisia. She had no family history of psychiatric illness.

In August 2018, she presented to the emergency room with an alleged history of ingestion of 12 tablets of blonanserin 8 mg. She was conscious, oriented, talking relevantly. As per patient, her parents stopped her medicines, and she was taken to various faith healers. The patient admitted auditory hallucinations and suicidal thoughts, and she reported that someone was controlling her thoughts. Systemic examination was normal, her pulse rate was 116/min, blood pressure 130/90 mm of Hg, and respiratory rate 18/min, and she was afebrile. Electrocardiogram was normal. She was admitted for observation, and baseline creatine phosphokinase was done which came out to be 28 U/L (reference range 26–140 U/L). The patient was managed conservatively and was discharged on the 3rd day in a stable condition. She had no sialorrhea, slurring of speech, tremors of body, or akathisia at the time of discharge.

On the 4th day, she presented in the outpatient department (OPD) with a history of restlessness and inability to sit or lie down due to restlessness from the last evening. She was weeping due to restlessness and was pacing in the room. Based on the history and clinical examination, a diagnosis of akathisia was made, and she was started on trihexyphenidyl 4 mg/day and amantadine 100 mg/day. Akathisia resolved in 2 days. Seven days later, she presented to OPD with weeping, sadness of mood, not feel like doing work or studying, and she had no psychotic symptoms. She was started on paroxetine 12.5 mg/day and blonanserin 4 mg/day, and trihexyphenidyl was stopped. Amantadine was stopped in the next visit. At present, she is doing well at blonanserin 4 mg and paroxetine 12.5 mg/day. No further episodes of akathisia were reported.

  Discussion Top

The amount of blonanserin ingested was four times the recommended maximum dose of 24 mg. Blonanserin-induced akathisia at overdose is understandable as blonanserin is associated with akathisia at therapeutic doses also, and the risk of akathisia is higher as compared to risperidone.[3],[5] Blonanserin overdose was not associated with hemodynamic changes, neurolept malignant syndrome, dystonia, sedation, sialorrhea, slurring of speech, or tremors of the body. To the best of our knowledge, this is the largest single-dose ingestion of blonanserin reported in the literature.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU, et al. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: Distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol 2013;36:223-38.  Back to cited text no. 1
Available from: http://www.medlineindia.com/list%20of%20approved%20drugs%20in%202012%20India.html. [Last accessed on 2019 Sep 03].  Back to cited text no. 2
Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2013;9:587-94.  Back to cited text no. 3
Chaudhari D, Shanker G, Gupta K. Two cases of blonanserin induced dyskinesia. Indian J Priv Psychiatry 2018;12:29-30.  Back to cited text no. 4
Nath S, Saraf AS, Mukherjee D. Blonanserin induced akathisia: A case report. Indian J Med Case Rep 2015;4:13-5.  Back to cited text no. 5


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Case Report

 Article Access Statistics
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal